Approximately 2 million people in the U.S. have epilepsy. Complex partial seizures occur in about 35% of persons with epilepsy.

Complex partial seizures result in impaired consciousness, with symptoms of decreased responsiveness and decreased awareness of self and surroundings. During a complex partial seizure, the patient may not communicate, respond to commands, or remember events that occurred, although some patients may make simple responses, follow simple commands, or continue to perform simple or, less commonly, complex motor behaviors such as operating a car. Complex partial seizures typically arise from the temporal lobe of the brain, an area near the side of the head, but may arise from any cortical region, area of the brain responsible for sensory and motor activities.

Marinus Pharmaceuticals has completed enrollment for its Phase 2a clinical trial of ganaxolone for the treatment of adult complex partial seizures.

To learn more about this clinical trial and for future studies of ganaxolone, please visit www.clinicaltrials.gov and search with keyword: MARINUS, you can also contact us at clinicaltrials@marinuspharma.com.